Exabis Library
Welcome to the e-CCO Library!
DOP35: Ambulatory care management of 70 patients with Acute Severe Ulcerative Colitis in comparison to 700 inpatients: Insights from a multicentre UK cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP35: Increasing incidence of pouchitis among patients undergoing ileal pouch-anal anastomosis between 1996 and 2018: A population-based Danish cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP36 Family-specific host genetic and gut microbial signatures have a beneficial role in early identification of familial inflammatory bowel diseases
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP36: Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP36: Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP36: Non-invasive assessment of postoperative disease recurrence in Crohn’s Disease: A multicenter, prospective cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP37 Neoplastic lesions outside diseased area in inflammatory bowel disease patients: A national cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP37: Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP37: Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP38 Prevalence of fatigue in a severe inflammatory bowel disease cohort highly exposed to biologics
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP38: An observational study to evaluate the burden of illness in patients with Crohn’s Disease with and without perianal fistulas in the USA
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP38: Upadacitinib Therapy Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP38: Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP39 The first prospective, multicentre, randomised controlled trial on discontinuation of infliximab in ulcerative colitis in remission; endoscopic normalisation does not guarantee successful withdrawal
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM